Effects Reverse transcriptase inhibitors (ATC J05AF) have antiviral properties against HIV. The effects are due to inhibition of the viral enzyme reverse transcriptase, which transcribes viral RNA into DNA and is important for viral replication. Structure and properties Within the drug group, two distinct classes are distinguished. The so-called nucleoside reverse transcriptase inhibitors, abbreviated NRTIs, … Reverse Transcriptase Inhibitors (HIV)
Products Dolutegravir was approved in the United States and EU in 2013 in film-coated tablet form (Tivicay). It was registered in many countries in 2014. A fixed-dose combination with dolutegravir, abacavir, and lamivudine is also available (Triumeq). In 2017, a combination product with rilpivirine was launched in the US (Juluca). It was approved in the … Dolutegravir
Products Rilpivirine has been commercially available in the EU and the United States since 2011 in tablet form (Edurant, combination products). In many countries, rilpivirine was approved in February 2013. Structure and properties Rilpivirine (C22H18N6, Mr = 366.4 g/mol) has a non-nucleoside structure. It is a diarylpyrimidine and is present in drugs as rilpivirine hydrochloride, … Rilpivirine
Products Various drugs containing tenofoviralafenamide are on the market worldwide. In many countries, tenofoviralafenamide was first approved in 2016 (United States: 2015). Biktarvy: bictegravir, emtricitabine, and tenofoviralafenamide (HIV). Genvoya: elvitegravir, cobicistat, emtricitabine, and tenofoviralafenamide (HIV). Descovy: emtricitabine and tenofoviralafenamide (HIV). Odefsey: emtricitabine, rilpivirine and tenofoviralafenamide (HIV). Symtuza: darunavir + cobicistat + emtricitabine + tenofoviralafenamide. Vemlidy: … Tenofoviralafenamide
